3-氯-6-(1H-咪唑并L-1-基)哒嗪 | 71037-71-3

• 物质功能分类: 医药中间体 - 杂环化合物 - 哒嗪类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 3-氯-6-(1H-咪唑并L-1-基)哒嗪
• 中文别名: 3-氯-6-(咪唑-1-基)-哒嗪；3-氯-6-(1H-咪唑)哒嗪
• 英文名称: 3-chloro-6-(1H-imidazol-1-yl)pyridazine
• 英文别名: 3-chloro-6-(imidazol-1-yl)pyridazine；3-chloro-6-imidazol-1-ylpyridazine
• CAS: 71037-71-3
• 化学式: C₇H₅ClN₄
• mdl: MFCD02323226
• 分子量: 180.596
• InChiKey: VAJLJRMHTTUOFQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  43.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933990090
• 储存条件：
  存储条件：2-8°C，密封，干燥。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 3-Chloro-6-(1H-imidazol-1-yl)pyridazine
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 3-Chloro-6-(1H-imidazol-1-yl)pyridazine
CAS number: 71037-71-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C7H5ClN4
Molecular weight: 180.6

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  3-氯-6-(1H-咪唑并L-1-基)哒嗪 在 potassium acetate 作用下， 以 氯仿 、 溶剂黄146 为溶剂， 以55%的产率得到6-(imidazol-1-yl)pyridazin-3(2H)-one
  参考文献：
  名称：

  3(2H)-pyridazinones and pharmaceutical compositions thereof

  摘要：

  本发明涉及一种新的3（2H）-吡啶酮衍生物，其通式为（I），包括含有它们的药物组合物以及它们的制备方法。在通式（I）中，##STR1##代表一个乙基或丙基基团，该基团被末端卤素原子或羟基或NR.sup.1R.sup.2基团取代，其中R.sup.1代表氢原子或未取代或可选择取代的苄基基团；R.sup.2代表氢原子或未取代或可选择取代的苯并[1,4]二噁烷-2-基甲基或-乙基基团或（CH.sub.2）.sub.n--R.sup.3基团，其中n为2或3；而R.sup.3代表未取代或可选择取代的苯氧基或苯硫基团；X代表氢原子或卤素原子或未取代或可选择取代的饱和或不饱和的5-或6-成员杂环基团，其中含有一个氮原子和可选择的另一个杂原子，例如氧、硫或氮原子，但要注意当X代表氢原子或氯原子时，R不同于被羟基或卤素原子末端取代的乙基或丙基基团。通式（I）化合物具有选择性抑制肾上腺素能α.sub.1受体、钙拮抗作用和降低血压的作用。

  公开号：

  US04826845A1
• 作为产物：
  描述：

  咪唑 、 3,6-二氯哒嗪 以 N,N-二甲基甲酰胺 为溶剂， 生成 3-氯-6-(1H-咪唑并L-1-基)哒嗪
  参考文献：
  名称：

  Anti-virally active pyridazinamines

  摘要：

  抗病毒活性吡啶并胺，含有该物质的组合物以及治疗温血动物病毒性疾病的方法。

  公开号：

  US05001125A1

文献信息

• Substituted diazabicycloalkane derivatives
  申请人：Basha Anwer

  公开号：US20050101602A1

  公开（公告）日：2005-05-12

  Compounds of formula (I) Z-Ar 1 —Ar 2 (I) wherein Z is a diazabicyclic amine, Ar 1 is a 5- or 6-membered aromatic ring, and Ar 2 is selected from the group consisting of an unsubstituted or substituted 5- or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazolyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.

  式(I)的化合物 Z-Ar 1 —Ar 2 (I) 其中Z是一种二氮杂双环胺，Ar 1 是一个5-或6-成员芳香环，Ar 2 选自未取代或取代的5-或6-成员杂芳基环；未取代或取代的双环杂芳基环；3,4-(亚甲二氧基)苯基；咔唑基；四氢咔唑基；萘基；和苯基；其中苯基在间位或对位上取代有0、1、2或3个取代基。这些化合物在治疗由α7 nAChR配体预防或改善的病症或紊乱中有用。还公开了包含式(I)的化合物的药物组合物以及使用这些化合物和组合物的方法。
• SPIRO COMPOUND AND USE THEREOF
  申请人：Taniguchi Takahiko

  公开号：US20100069351A1

  公开（公告）日：2010-03-18

  The present invention aims to provide a novel SCD inhibitor. The present invention relate to SCD inhibitor comprising A compound represented by the formula (I) wherein R is an optionally substituted cyclic group or an optionally substituted carbamoyl group, provided that R is not an optionally substituted 7-pyrido[2,3-d]pyrimidyl group; ring A is an optionally further substituted pyridazine ring; R 1 , R 2 , R 3 , R 4 , R 11 , R 12 , R 13 and R 14 are each independently a hydrogen atom or a substituent, or R 1 and R 11 in combination, R 2 and R 12 in combination, R 3 and R 13 in combination, or R 4 and R 14 in combination optionally form an oxo group, or R 2 and R 4 in combination optionally form a bond or an alkylene cross-linkage; m and n are each independently an integer of 0 to 2; ring B is an optionally substituted ring, provided that the two atoms constituting ring B, which are adjacent to the spiro carbon atom, are not oxygen atoms at the same time, or a salt thereof, or a prodrug thereof.

  本发明旨在提供一种新型SCD抑制剂。本发明涉及一种包括下式（I）所表示的化合物的SCD抑制剂：其中R是一个可选择取代的环基或可选择取代的氨甲酰基，但R不是一个可选择取代的7-吡啶并[2,3-d]嘧啶基团；环A是一个可选择进一步取代的吡啶并嘧啶环；R1、R2、R3、R4、R11、R12、R13和R14分别独立地是氢原子或取代基，或R1和R11的组合体，R2和R12的组合体，R3和R13的组合体，或R4和R14的组合体可选择形成氧基，或R2和R4的组合体可选择形成键或烷基交联；m和n分别独立地是0到2的整数；环B是一个可选择取代的环，但构成环B的两个与螺碳原子相邻的原子不同时为氧原子，或其盐，或其前药。
• Synthesis and antihypertensive activity of new 6-heteroaryl-3-hydrazinopyridazine derivatives
  作者：Gerd Steiner、Josef Gries、Dieter Lenke

  DOI：10.1021/jm00133a013

  日期：1981.1

  examined on normotensive and spontaneously hypertensive rats by comparison with dihydralazine (I). 6-Imidazol-1-yl derivatives have proved particularly active. Of these derivatives, 3-hydrazino-6-(2-methylimidazol-1-yl)pyridazine (7c) achieves 4.9 times the activity of dihydralazine when administered orally to spontaneously hypertensive rats. The LD50 values of 7c and dihydralazine are very similar.

  描述了具有抗高血压作用的新型6-杂芳基-3-肼基哒嗪的合成和药理活性。通过三种不同的合成方法将吡咯，吡唑，咪唑，三唑，四唑，噻吩，吲哚和咔唑杂环引入到哒嗪核的6位。通过与二肼苯哒嗪（I）进行比较，对降压和自发性高血压大鼠的降压作用进行了检查。已证明6-咪唑-1-基衍生物具有特别的活性。在这些衍生物中，当对自发性高血压大鼠口服时，3-肼基-6-（2-甲基咪唑-1-基）哒嗪（7c）的活性是二肼苯哒嗪的4.9倍。7c和二肼苯哒嗪的LD50值非常相似。
• PYRIDAZINE COMPOUND
  申请人：Takeda Pharmaceutical Company Limited

  公开号：EP3118200A1

  公开（公告）日：2017-01-18

  The present provides a pyridazine compound having an inhibiting effect on Stearoyl-CoA desaturase (SCD) (in particular, SCD1). The present provides a compound represented by formula (where each symbol is as defined as in the Specification) or a salt thereof

  本发明提供了一种对硬脂酰辅酶A去饱和酶（SCD）（特别是SCD1）具有抑制作用的吡啶啉化合物。本发明提供了一种由以下公式表示的化合物（其中每个符号如规范中定义）或其盐。
• [EN] SUBSTITUTED DIAZABICYCLOALKANE DERIVATIVES AS LIGANDS AT ALPHA 7 NICOTINIC ACETY LCHOLINE RECEPTORS<br/>[FR] DERIVES DE DIAZABICYCLOALCANE SUBSTITUES UTILISES EN TANT QUE LIGANDS AU NIVEAU DES RECEPTEURS ALPHA 7 DE L'ACETYLCHOLINE NICOTINIQUE
  申请人：ABBOTT LAB

  公开号：WO2005028477A1

  公开（公告）日：2005-03-31

  Compounds of formula (I) Z-Ar 1 -Ar 2 wherein Z is a diazabicyclic amine, Ar 1 is a 5- or 6-membered aromatic ring, and Ar 2 is selected from the group consisting of an unsubstituted or substituted 5- or 6-membered heteroaryl ring; unsubstituted or substituted bicyclic heteroaryl ring; 3,4-(methylenedioxy)phenyl; carbazolyl; tetrahydrocarbazolyl; naphthyl; and phenyl; wherein the phenyl is substituted with 0, 1, 2, or 3 substituents in the meta- or para-positions. The compounds are useful in treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands. Also disclosed are pharmaceutical compositions comprising compounds of formula (I) and methods for using such compounds and compositions.

  化合物的公式（I）为Z-Ar1-Ar2，其中Z是一种二氮杂双环胺，Ar1是一种5-或6-成员的芳香环，而Ar2则选自于未取代或取代的5-或6-成员杂芳基环；未取代或取代的双环杂芳基环；3,4-（亚甲氧基）苯基；咔唑基；四氢咔唑基；萘基；以及苯基；其中苯基在间位或对位上取代有0、1、2或3个取代基。这些化合物在治疗由α7 nAChR配体预防或缓解的疾病或疾病状态中有用。此外，还披露了包含公式（I）化合物的制药组合物以及使用这些化合物和组合物的方法。